Host-Directed Therapies for Tuberculosis

• Muut tekijät: Venketaraman, Vishwanath (Toimittaja)
• Aineistotyyppi: Elektroninen Kirjan osa
• Kieli: englanti
• Julkaistu: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Aiheet: Research & information: general; Biology, life sciences; Mycobacterium tuberculosis; host-directed therapies; immune responses; tuberculosis; lung cancer; misdiagnosis; invasive procedure; revising; antiplatelet; aspirin; immunomodulation; survival; Taiwan; latent infection; pulmonary; rabbit; iron supplementation; pathology; immune response; gene expression; Perls' stain; autophagy; M. tb; BCG vaccination; immune exhaustion; glutathione; cytokines; granulomas; type 2 diabetes; co-morbidities; co-infections; inflammation; redox imbalance; antioxidants
• Linkit: DOAB: download the publication; DOAB: description of the publication

Yhteenveto

TB is considered as one of the oldest documented infectious diseases in the world and is believed to be the leading cause of mortality due to a single infectious agent. Mtb, the causative agent responsible for TB, continues to afflict millions of people worldwide. Furthermore, one-third of the entire world's population has latent TB. Consequently, there has been a worldwide effort to eradicate and limit the spread of Mtb through the use of antibiotics. However, management of TB is becoming more challenging with the emergence of drug-resistant and multi-drug resistant strains of Mtb. Furthermore, when administered, many of the anti-TB drugs commonly present severe complications and side effects. Novel approaches to enhance the host immune responses to completely eradicate Mtb infection are urgently needed. This Special Issue will therefore cover most recent advances in the area of host-directed therapies for TB.

Ulkoasu

1 electronic resource (120 p.)

ISBN

books978-3-03943-502-9
9783039435012
9783039435029

Pääsy

Open Access